JenaValve Technology announced the 30-day results of its post-market registry (JUPITER), which is evaluating the five-year long term safety and effectiveness of the company’s second-generation transapical, transcatheter aortic valve implantation (TAVI) system in 180 elderly high-risk patients, at EuroPCR (21–24 May, Paris, France).
According to a press release, the 30-day results of the first half of the patients enrolled in the JUPITER registry showed that JenaValve was associated with a high procedural success rates and excellent clinical outcomes.
In 88 patients with a mean logistic EuroSCORE of 24.9%, the procedural success rate was 95.5%. Major adverse events such as major stroke (0.0%) or spontaneous myocardial infarction (1.3%) were very low and represent the safety of the JenaValve TAVI system. The press release also reported that excellent haemodynamics and very low paravalvular leakage confirm the advantages of the system; 97.6% of the patients had a paravalvular leakage ≤mild, severe paravalvular leakage did not occur (0.0%).
The data was presented by Stephan Ensminger, from the Heart and Diabetes Center, NRW in Bad Oeynhausen, Germany, on behalf of the registry investigators. He said: “The JUPITER registry confirms the excellent performance and safety of this second generation TAVI system in a real world clinical use.”
